QBD driven optimized approach for formulation of ginkgo biloba extract -fast dissolving oral films (FDOF’S)

As Alzheimer's disease (AD) advances, cholinergic dysfunction, β-amyloid plaques and neurofibrillary tangle development, oxidative damage, and neuroinflammation occur, making the major addressal setting the health care environment. Though less successful than a synthetic method, the therapy of AD has focused on cholinergic dysfunction, inflammation, and oxidative damage. Neurodegenerative diseases are treated commercially with gingko biloba extract. FDOFs are therefore effective in changing and enhancing the bioavailability of nutraceuticals. FDOFs of Gingko biloba extract were formulated using QbD 33 factorial designs in the current study, and the optimal formulations were examined for both in-vitro and in-vivo models of Alzheimer's disease. Twelve formulations have been prepared and described in compliance with ICH guidelines. The formulations F7 and F10 were chosen because of their optimal formulation properties.